Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19280743 | 1.00 | CYP1A2 (0.39) | CYP1A2GRM5FFAR1HDAC4HDAC2 | |
| SCHEMBL2193339 | 1.00 | — | — | |
| SCHEMBL262534 | 0.97 | — | — | |
| SCHEMBL262240 | 0.90 | — | — | |
| SCHEMBL18828533 | 0.75 | CYP1A2 (0.39) | CYP1A2GRM5FFAR1HDAC4HDAC2 | |
| SCHEMBL150206 | 0.75 | — | — | |
| SCHEMBL8197420 | 0.75 | CYP1A2 (0.39) | CYP1A2GRM5FFAR1HDAC4HDAC2 | |
| SCHEMBL8197417 | 0.75 | CYP1A2 (0.39) | CYP1A2GRM5FFAR1HDAC4HDAC2 | |
| SCHEMBL10457078 | 0.75 | CYP1A2 (0.39) | CYP1A2GRM5FFAR1HDAC4HDAC2 | |
| SCHEMBL11331379 | 0.75 | CYP1A2 (0.39) | CYP1A2GRM5FFAR1HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753385-B2 | Method for producing kakeromycin and derivatives thereof | OP BIO FACTORY CO., LTD. (JP) | 2023-09-12 | — | — | US | disclosed |
| CN-115160248-A | Method for producing Kakeromycin and derivatives thereof | 海洋规划生物工厂株式会社 | 2022-10-11 | — | — | CN | disclosed |
| CN-114874131-A | Method for producing Kakeromycin and derivatives thereof | 海洋规划生物工厂株式会社 | 2022-08-09 | — | — | CN | disclosed |
| CN-114835596-A | Method for producing Kakeromycin and derivatives thereof | 海洋规划生物工厂株式会社 | 2022-08-02 | — | — | CN | disclosed |
| CN-107709335-B | Method for producing Kakeromycin and derivatives thereof | 海洋规划生物工厂株式会社 | 2022-05-31 | — | — | CN | disclosed |
| US-20220024883-A1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | OP BIO FACTORY CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| EP-3263572-B1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | SEED RES INSTITUTE CO LTD (JP) | 2021-12-15 | — | — | EP | disclosed |
| US-11155526-B2 | Method for producing kakeromycin and derivatives thereof | OP BIO FACTORY CO., LTD. (JP) | 2021-10-26 | — | — | US | disclosed |
| US-11066374-B2 | Method for producing kakeromycin and derivatives thereof | OP BIO FACTORY CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-10703732-B2 | Method for producing kakeromycin and derivatives thereof | OP BIO FACTORY CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | disclosed |
| US-5436254-A | Vaopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4006122-A | STORAGE STABLE | THE UPJOHN COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | CYP1A2 37/4885GRM5 481/4885FFAR1 2327/4885 |
| US-11753385-B2 | Method for producing kakeromycin and derivatives thereof | ERG28, CYP51A1, NISCH | CYP1A2 169/4885GRM5 4717/4885FFAR1 3990/4885 |
| US-11155526-B2 | Method for producing kakeromycin and derivatives thereof | ERG28, CYP51A1, NISCH | CYP1A2 169/4885GRM5 4717/4885FFAR1 3990/4885 |
| US-10703732-B2 | Method for producing kakeromycin and derivatives thereof | ERG28, CYP51A1, NISCH | CYP1A2 169/4885GRM5 4717/4885FFAR1 3990/4885 |
| US-20220024883-A1 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | ERG28, CYP51A1, NISCH | CYP1A2 169/4885GRM5 4717/4885FFAR1 3990/4885 |
| US-11066374-B2 | Method for producing kakeromycin and derivatives thereof | ERG28, CYP51A1, NISCH | CYP1A2 169/4885GRM5 4717/4885FFAR1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.